APrevent® VOIS-Implant: To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
Study summary
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Male and female patients between 18 and 80 years
* Diagnosed with permanent UVFP and insufficient glottal closure
* A significant voice disorder as measured by perceptual rating (Grade ≥2 GRBAS Scale) and Voice Handicap Index (VHI-30 score \>33)
* Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
* Ability to co-operate with the Investigator and to comply with the requirements of the entire study
* Availability to volunteer for the entire study duration, willing to adhere to all protocol requirements and willing and able to give informed consent for participation
Exclusion Criteria:
* Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the clinical investigation may influence the result of the clinical investigation, or the participant's ability to participate in the clinical investigation
* Scheduled elective surgery or other procedures requiring general anaesthesia during clinical investigation
* Bilateral vocal fold paralysis
* Had injection medialization laryngoplasty with the injectable still being within the double length of the maximum resorption time frame as stated in their approval or as supported by literature.
* Presence of structural vocal fold lesions such as polyp or nodules
* Presence of oropharyngeal or laryngeal tumors
* Patients with diagnosed severe obstructive sleep apnea (OSA)
* Status post total cordectomy
* Previous laryngeal framework surgery (any type of thyroplasty, arytenoid adduction)
* Status post tracheostomy
* Presence of acute systemic infection at time of screening or shortly before surgery
* Significant non-laryngeal speech abnormality (severe dysarthria determined by a panel of trained speech therapists)
* Severe coagulopathy
* Females who are pregnant, lactating or planning pregnancy are excluded from the investigation
* Patients with bil. Gr. III-IV hypertrophic tonsils
* Diabetes mellitus with poor control and poor wound healing history
Primary outcome measure(s)
Change in G-Score from GRBAS-Scale — 7weeks Change in G-Score from GRBAS-Scale from before to 7 weeks after permanent APrevent® VOIS implantation
Trial sites (7)
Facility
City
Region
Status
Mayo Clinic - Phoenix
Phoenix
Arizona
Recruiting
Greater Baltimore Medical Center
Baltimore
Maryland
Recruiting
Cleveland Clinic
Cleveland
Ohio
Not Yet Recruiting
The University of Texas Health Science Center at Houston
Houston
Texas
Recruiting
Medical University of Vienna
Vienna
Austria
Recruiting
SRH Wald-Klinikum Gera
Gera
Germany
Recruiting
University Medical Center
Hamburg
Germany
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.